Bio-Rad Laboratories has experienced significant volatility in the face of macroeconomic uncertainties, with concerns raised over limited growth potential due to inconsistent financials. Despite this, its stocks have soared and analysts have updated their estimates following Q2 results. Notably, it has launched new Digital PCR Systems in 2025 which have resulted in surges in stock value. Institutional investors are buying Bio-Rad stock, indicating confidence in its growth potential despite the recent 5.0% drop taking three-year losses to 61%. The company posted strong performance in Q2 2025, swinging into profit. Yet, analysts have been trimming their price target after its latest report, prompting questions over the optimism surrounding its outlook. The stock draws interest for its low debt and potential undervalued status following a drop in the stock price. It remains a favourite amongst institutional investors and eventually received a PT boost from Wells Fargo, yet confidence is lacking as shares have slipped recently. Driven by a weak academic research market, guidance has lowered, despite a significant Q2 earnings beat, and RBC Capital raising its target price to $387.
Bio-Rad Laboratories Stocks News Analytics from Mon, 11 Nov 2024 08:00:00 GMT to Thu, 07 Aug 2025 11:30:00 GMT -
Rating 1
- Rumor -3
